- Home
- NEN vs IMMP Comparison
NEN vs IMMP Comparison
Compare NEN & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEN
- IMMP
- Stock Information
- Founded
- NEN 1977
- IMMP 1987
- Country
- NEN United States
- IMMP Australia
- Employees
- NEN N/A
- IMMP N/A
- Industry
- NEN Building operators
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- NEN Real Estate
- IMMP Health Care
- Exchange
- NEN Nasdaq
- IMMP Nasdaq
- Market Cap
- NEN 262.4M
- IMMP 251.8M
- IPO Year
- NEN N/A
- IMMP N/A
- Fundamental
- Price
- NEN $72.50
- IMMP $1.69
- Analyst Decision
- NEN
- IMMP Buy
- Analyst Count
- NEN 0
- IMMP 1
- Target Price
- NEN N/A
- IMMP $7.00
- AVG Volume (30 Days)
- NEN 341.0
- IMMP 88.9K
- Earning Date
- NEN 01-01-0001
- IMMP 10-21-2025
- Dividend Yield
- NEN 6.66%
- IMMP N/A
- EPS Growth
- NEN 34.86
- IMMP N/A
- EPS
- NEN 4.59
- IMMP N/A
- Revenue
- NEN $83,884,808.00
- IMMP $3,306,742.00
- Revenue This Year
- NEN N/A
- IMMP N/A
- Revenue Next Year
- NEN N/A
- IMMP $725.37
- P/E Ratio
- NEN $15.80
- IMMP N/A
- Revenue Growth
- NEN 4.96
- IMMP 31.28
- 52 Week Low
- NEN $71.00
- IMMP $1.32
- 52 Week High
- NEN $84.00
- IMMP $2.71
- Technical
- Relative Strength Index (RSI)
- NEN 60.24
- IMMP 50.94
- Support Level
- NEN $71.00
- IMMP $1.60
- Resistance Level
- NEN $72.00
- IMMP $1.76
- Average True Range (ATR)
- NEN 0.19
- IMMP 0.06
- MACD
- NEN 0.12
- IMMP 0.01
- Stochastic Oscillator
- NEN 100.00
- IMMP 58.82
About NEN New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership
New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating and selling real estate. The Partnership owns and operates various residential apartments, condominium units and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.